Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2

2018 ◽  
Vol 109 (5) ◽  
Author(s):  
Roberta Semprini ◽  
Alessandro Martorana ◽  
Mauro Ragonese ◽  
Caterina Motta
Keyword(s):  
Nerve Conduction Study ◽  
Nerve Conduction ◽  
Diabetes Type ◽  
Motor Neuropathy ◽  
Diabetes Type 1 ◽  
Sensory Motor ◽  
Patients With Diabetes

scholarly journals Midterm Fate of the Contralateral Foot in Charcot Arthropathy

2020 ◽  
Vol 41 (10) ◽  
pp. 1181-1189
Author(s):  
Felix W. A. Waibel ◽  
Martin C. Berli ◽  
Viviane Gratwohl ◽  
Kati Sairanen ◽  
Dominik Kaiser ◽  
...  
Keyword(s):  
Diabetes Type 2 ◽  
Female Gender ◽  
Major Amputation ◽  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Charcot Arthropathy ◽  
Level Of Evidence ◽  
Patients With Diabetes

Background: The contralateral foot in Charcot arthropathy or neuroarthropathy (CN) is subject to increased plantar pressure. To date, the clinical consequences of this pressure elevation are yet to be determined. The aim of this study was to evaluate ulcer and amputation rates of the contralateral foot in CN. Methods: We abstracted the medical records of 130 consecutive subjects with unilateral CN. Rates of contralateral CN development and recurrence, contralateral ulcer development, and contralateral amputations were recorded. Statistical analysis was performed to identify possible risk factors for contralateral CN and ulcer development, and contralateral amputation. Mean follow-up was 6.2 (SD 4) years. Results: After a mean of 2.5 years, 19.2% patients developed contralateral CN. Female gender was associated with contralateral CN development (odds ratio 3.13, 95% confidence interval 1.27, 7.7). Overall, 46.2% patients developed a contralateral ulcer. Among the patients who developed contralateral CN, 60% developed an ulcer. Sanders type 2 at the index foot (midfoot CN) was significantly associated with contralateral ulcer development. Ulcer-free survival (UFS) differed significantly between patients with diabetes type 1 (median UFS 5131 days) and patients with diabetes type 2 (median UFS 2158 days). A total of 25 amputations had to be performed in 22 (16.9%) patients. Three of those 22 patients (2.3%) needed major amputation. Conclusion: Almost 20% of patients developed contralateral CN. Nearly half of people with CN developed a contralateral foot ulceration. Patients with type 2 diabetes had significantly shorter UFS than patients with diabetes type 1. Every sixth patient needed an amputation, with the majority being minor amputations. The contralateral foot should be monitored closely and included in the treatment in patients with CN. Level of Evidence: Level IV, retrospective study.

Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes – What We Know so Far and the Missing Links

2017 ◽  
Vol 127 (08) ◽  
pp. 497-504 ◽  
Author(s):  
Jan Benedikt Groener ◽  
Dimitrios Oikonomou ◽  
Ruan Cheko ◽  
Zoltan Kender ◽  
Johanna Zemva ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Absolute Risk ◽  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Patients With Diabetes

AbstractHyperglycemia explains the development of late diabetic complications in patients with diabetes type 1 and type 2 only partially. Most therapeutic efforts relying on intensive glucose control failed to decrease the absolute risk for complications by more than 10%, especially in patients with diabetes type 2. Therefore, alternative pathophysiological pathways have to be examined, in order to develop more individualized treatment options for patients with diabetes in the future. One such pathway might be the metabolism of dicarbonyls, among them methylglyoxal and the accumulation of advanced glycation end products. Here we review currently available epidemiological data on dicarbonyls and AGEs in association with human diabetes type 1 and type 2.

P612: Small and large fibre neuropathy in patients with diabetes type 1 compared with type 2: a follow-up study

2014 ◽  
Vol 125 ◽  
pp. S215
Author(s):  
S. Løseth ◽  
E. Stålberg ◽  
S. Lindal ◽  
R. Jorde ◽  
S.I. Mellgren
Keyword(s):  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Follow Up Study ◽  
Patients With Diabetes ◽  
Large Fibre

scholarly journals Nonspecific body reactivity in patients with diabetes mellitus depending on its type

2014 ◽  
Vol 18 (2 (70)) ◽  
Author(s):  
O. A. Olenovych
Keyword(s):  
Diabetes Mellitus ◽  
Immune System ◽  
Functional Activity ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Immune Defense ◽  
Diabetes Type 1 ◽  
Patients With Diabetes

According to the results of complex assessment of integral haematological coefficients the development of endogenous intoxication was revealed in case of diabetes mellitus, whose intensity depends on the type of the disease and causes immune system disorganization. The decrease of functional activity of specific immunity as well as nonspecific one in case of diabetes mellitus leads to deregulation of cellular and humoral reactions and depends on diabetes type: in diabetes type 1 the reduction of nonspecific immunoresistance is contributed by microphages, in diabetes type 2 – by macrophages, accompanied by the deficiency of specific immune defense, reliably more significant in diabetes type 2.

scholarly journals Analysis of the quality of life of patients with type 1 diabetes mellitus in real clinical practice who received insulin degludec

2021 ◽  
pp. 96-103
Author(s):  
L. A. Suplotova ◽  
A. S. Sudnitsyna ◽  
N. V. Romanova
Keyword(s):  
Quality Of Life ◽  
Type 1 Diabetes ◽  
Diabetes Type ◽  
Insulin Degludec ◽  
Diabetes Type 1 ◽  
Glucose Levels ◽  
Patients With Diabetes ◽  
Long Acting

Introduction. Long-term and high-quality glycemic control prevents the development of vascular complications of diabetes type 1 and improves the disease prognosis, significantly increasing life expectancy. A decrease in the quality of life (QOL) of patients with diabetes type 1 is associated with the disease complications development and carbohydrate metabolism status. In connection with the proven advantages of using indicators of time spent in glycemic ranges (TIR, TAR, TBR), the study of their associations with QOL in patients with type 1 diabetes when switching from long-acting analog insulins to insulin degludec is of particular interest.Aims. To assess the quality of life with diabetes type 1 when switching from long-acting analogs to insulin degludec in real world clinical practice.Materials and methods. The study was designed as a prospective, single-center, uncontrolled study. The recruitment of patients with diabetes type 1 who did not achieve the target values of control of carbohydrate metabolism control, who were on therapy with long-acting and ultrashort-acting analog insulin therapy, was carried out in accordance with the matching criteria. The calculation of TIR and TBR was carried out employing the data from professional continuous monitoring of glucose levels and selfmonitoring of blood glucose levels. The SF-36 Health Status Survey was used to assess QoL.Results. The study included 26 patients who met the inclusion criteria and did not have the exclusion criteria. The relationships between TIR, TBR and QoL parameters during insulin degludec therapy were revealed - with vitality, bodily pain, mental health, which demonstrates an increase in QoL mainly due to the mental component of health.Conclusions. Switching patients with type 1 diabetes from long-acting analog insulins to ultra-long-acting analog insulin on an outpatient basis provides an improvement in glycemic control due to HbA1c and TIR, TBR, and also increases QOL satisfaction, mainly due to the mental component of health.

Sign in / Sign up

Export Citation Format

Share Document